Second HERA Invest agreement signed to advance therapies against antimicrobial resistance
HERA has today signed the second agreement under HERA Invest, its pioneering financial mechanism designed to support the research and development of medical countermeasures (MCMs) and technologies to address priority cross-border health threats.
Read the news announcement published by Directorate-General for Research and Innovation on 9 December 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (12 janvier 2025). Second HERA Invest agreement signed to advance therapies against antimicrobial resistance. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/132em





